Serina Therapeutics, based in Alameda, California, is a clinical-stage biotechnology company developing drug candidates for neurological diseases, focusing on SER-252 for Parkinson's Disease. The company went public on November 29, 2018, and employs four people.
AgeX Therapeutics (SER) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, AgeX Therapeutics's actual EPS was -$0.49, beating the estimate of -$0.63 per share, resulting in a 21.75% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
